

### Certificate of analysis

DRICUi016-A

Operator: SH Ellwood Date: 23/06/2023

Supervisor: SA Cowley Date: 02/08/2023

Signature: SA Consley


### Source of cells and reprogramming information

- GU66A10008a T cells from Cardiff 16/12/2021
- Reprogrammed at UOXF AKA IPMAR19
- Reprogrammed on 04/2022 SC
- Reprogramming system Cytotune v2
- Clone DRICUi016-A = IPMAR19A4
- Banked at p13 10/2022 SE

# Viability post-thaw and Morphology according to JMSCFSOP19 passage 14


- Vial cell count immediately post-thaw 2.32 x 10<sup>6</sup>
- Viability immediately post-thaw 92.9%
- Photo at day 3 post-thaw (scale bar = 100μm):

Day 3 post-thaw, 20% plated to 1w.6wp



# Sendai Cytotune 2 clearance: according to Cytotune manual

KOS and Klf4 undeterminable but Virus backbone and c-Myc undetectable at passage 10 so overall pass



Product sizes: SeV 181bp; KOS 528bp; SeV-Klf 410bp; SeV-Myc 532bp; Actin 623bp

### Sterility:

Mycoplasma Test: According to MycoAlert Lonza LT07-318 undetectable at passage 14.

Visual inspection of thawed cells cultured without antibiotic/antimycotic for 4 days: no evidence of bacteria, yeast or fungus.

Sample	Clone	Passage number	Initial	Reading 1	Reading 2	Ratio/Status
+ve control				5.25	61.96	11.80
-ve control				6.158	0.414	0.07
	IPMAR19A4 DRICUI016-A	p14	SE	2.279	0.955	0.42

### Results mean:


Ratio 0 - 0.999 negative for mycoplasma

Ratio 1 – 1.3 Borderline Result (retest required)


Ratio above 1.3 positive for mycoplasma

# Flow cytometric analysis according to JMSCFSOP05 passage 14

DRICUi016 Tra-1-60 87.6%




DRICUi016 Nanog 77.3%



# Illumina GSA SNP analysis according to JMSCFSOP16

- Passage 13
- Identity to parent PBMC confirmed
- Karyotype abnormalities:
  - No gross abnormalities detected vs PBMC


# Alignment of GU66A10008A PBMC SNPs with DRICUi016-A



Regression Coefficient

 $R^2: 0.9877$ 

### Karyogram GU66A10008a PBMC



### Karyogram DRICUi016-A

